Atea Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Atea Pharmaceuticals' es Jean-Pierre Sommadossi , nombrado en Jul 2012, tiene una permanencia de 12.08 años. compensación anual total es $5.93M, compuesta por 11.5% salario y 88.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 7.16% de las acciones de la empresa, por valor de $22.95M. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 4.9 años, respectivamente.
Información clave
Jean-Pierre Sommadossi
Chief Executive Officer (CEO)
US$5.9m
Compensación total
| Porcentaje del salario del CEO | 11.5% |
| Permanencia del CEO | 12.2yrs |
| Participación del CEO | 7.1% |
| Permanencia media de la dirección | 4.1yrs |
| Promedio de permanencia en la Junta Directiva | 5yrs |
Actualizaciones recientes de la dirección
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
Compensación vs. Mercado: La compensación total de Jean-Pierre($USD5.93M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.41M).
Compensación vs. Ingresos: La compensación de Jean-Pierre ha aumentado mientras la empresa no es rentable.
CEO
Jean-Pierre Sommadossi (68 yo)
12.2yrs
Permanencia
US$5,925,790
Compensación
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 12.2yrs | US$5.93m | 7.09% $ 20.6m | |
| CFO, Executive VP of Legal & Secretary | 10.8yrs | US$1.96m | 0.79% $ 2.3m | |
| Executive VP of Finance & Chief Accounting Officer | 2.7yrs | US$1.52m | 0.025% $ 71.8k | |
| Chief Development Officer | 4.1yrs | US$2.11m | 0.042% $ 121.7k | |
| Chief Medical Officer | 4.1yrs | US$1.85m | 0.030% $ 88.3k | |
| Senior Vice President of Investor Relations & Corporate Communications | 3.7yrs | sin datos | sin datos | |
| Vice President of Marketing | 2.7yrs | sin datos | sin datos | |
| Executive Vice President of Chemistry | no data | sin datos | sin datos | |
| Executive Vice President of Early Stage Development | no data | sin datos | sin datos | |
| Chief Commercial Officer | 5.9yrs | US$1.52m | 0.12% $ 357.8k | |
| Executive VP of Clinical Sciences & Project Management | 4.7yrs | sin datos | sin datos | |
| Executive Vice President of Regulatory Affairs | 3.7yrs | sin datos | sin datos |
4.1yrs
Permanencia media
61.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AVIR se considera experimentado (4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 12.2yrs | US$5.93m | 7.09% $ 20.6m | |
| Independent Director | 3.9yrs | US$332.10k | 0.039% $ 114.0k | |
| Independent Director | 10yrs | US$324.60k | 0.098% $ 286.0k | |
| Lead Independent Director | 5yrs | US$357.10k | 0.96% $ 2.8m | |
| Independent Director | 9.8yrs | US$324.60k | 0.078% $ 225.7k | |
| Independent Director | 4.1yrs | US$327.10k | 0.067% $ 194.2k | |
| Independent Director | 3.3yrs | US$442.10k | 0.039% $ 114.0k |
5.0yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de AVIR se considera experimentada (4.9 años de antigüedad promedio).